Navigation Links
An adjuvant chemotherapeutic agent in gastric cancer therapy
Date:2/17/2009

Peritoneal carcinomatosis can be thought of as a series of events that together form a peritoneal metastatic cascade. The peritoneal stromal tissue appears to be a friendly host for tumour proliferation, providing a rich source of growth factors and chemokines known to be involved in tumour metastasis. Till now, our understanding of the molecular mediators that orchestrate this cascade is weakly understood. Astragalus memebranaceus,a traditional chinese herbal medicine used for the treatment of common cold , diarrhea, fatigue anorexia and cardiac diseases. In recent years, it has been proposed that Astragalus may possess anti-apoptosis potential in peritoneal mesothelial cell. In spite of this, the anti-apoptosis effects of Astragalus saponin extract in human peritoneal mesothelial cells during peritoneal carcinomatosishas has not been studied. In this study, the anti-apoptosis effects of Astragalus saponin extract were investigated in human peritoneal mesothelial cells during peritoneal gastric cancer metastasis.

A research article to be published on February 7, 2009 in the World Journal of Gastroenterology addresses this question. The research team led by Professor Hui-Mian Xu from Department of Oncology, The First Affiliated Hospital, China Medical University.Human peritoneal mesothelial cell line HMrSV5 was co-incubated with gastric cancer cell supernatant and/or Astragalus injection. Morphological changes were observed. Apoptosis was determined by transmission electron microscope. Apoptosis was also quantified by two methods: the detection of acridine orange/ethidium bromide-stained condensed nuclei by fluorescent microscopy and flow cytometry. The expressions of Bcl-2 and Bax were evaluated by immunostaining.

After 24h of being treated with gastric cancer cell supernatant, mesothelial cells presented morphological changes, exfoliation happened and naked areas appeared.

Cell supernatant from gastric cancer cell MKN45 w
'/>"/>

Contact: Lin Tian
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Nanoemulsion-Based Intranasal Influenza Vaccine Adjuvant Triggers Robust Immunity Using Significantly Less Antigen
2. Cancer patients who receive neoadjuvant therapy followed by mastectomy may not need radiation
3. Genomic Health Announces Oncotype DX(R) Provides Additional Prognostic Benefit in Patients Assessed With Adjuvant Online
4. Infectious Disease Research Institute Receives Grant from the Bill & Melinda Gates Foundation for Adjuvant Access and Development
5. A new chemotherapeutic target for hepatocellular carcinoma
6. Senior Market Sales Offers Discounted E&O Insurance for Agents
7. An Oral Agent for the Treatment of Moderate to Severe Psoriasis Would Earn a Higher Patient Share in the United States than in Europe
8. CRi to Distribute VisEn Medicals Portfolio of Fluorescence In Vivo Imaging Agents and Labels in North America
9. Rapid Generic Erosion of Branded Agents, Including Market-Leading Viagra, Will Cause Sales of Erectile Dysfunction Drugs to Remain Flat Over the Next Decade
10. RE/MAX Northern Illinois Real Estate Agents Raises $284,000 For CMN In 2008, An 18 Percent Increase Over Prior Year
11. Aflac Agents and Employees Boost Bone Marrow Registry
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Free Wheelchair Mission Breaks List of Top 60 OC Nonprofits in 2009 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Cancer survivors at greater risk of birth complications 3B special monitoring needed 50498 1Cancer survivors at greater risk of birth complications 3B special monitoring needed 50498 2Meltzer and Yancy to Lead American Heart Association in 2009 10 50496 1Meltzer and Yancy to Lead American Heart Association in 2009 10 50496 2Meltzer and Yancy to Lead American Heart Association in 2009 10 50496 3Calling All Runners 3A Join the Fight Against Cancer 50493 1Calling All Runners 3A Join the Fight Against Cancer 50493 2